First vaccine approved by FDA to prevent serogroup B Meningococcal disease.

On October 29, 2014, the U.S. Food and Drug Administration announced the approval of Trumenba, the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.  Of the 500 cases of meningococcal disease reported in the United States in 2012, 160 were caused by serogroup B, according to the U.S. Centers for Disease Control and Prevention.

While we are still awaiting an official recommendation of the ACIP and incorporation into the existing immunization schedule, prescribing information shows that the new vaccine is to be administered as a 3-dose series at months 0, 2 and 6 in the 10 through 25 year old age group.

Trumenba is manufactured by Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania.

CDC issues new pneumococcal vaccine recommendations for adults age 65 years and older.

At the AAFP Scientific Assembly last week, Dr. Vincent Hsu, Infectious Diseases Specialist, presented Immunization Update: Improving Immunizations in 2014 to the Family Physicians in attendance. In his presentation, Dr. Hsu mentioned that the Centers for Disease Control and Prevention (CDC) released new pneumococcal vaccine recommendations for adults age 65 years and older in the September 19 issue of Morbidity and Mortality Weekly Report.  The new recommendations involve using both pneumococcal conjugate vaccines – Prevnar 13 and Pneumovax 23 and are summarized below:

  • Patient history: No previous pneumococcal vaccine (of either type or at any age) or pneumococcal vaccination history unknown Give: PCV13 at age 65 (or older) followed by PPSV23 6–12 months later.
  • Patient history: Previous dose of PPSV23 vaccine received at age 65 or older Give: PCV13 at least one year after the PPSV23 dose.
  • Patient History: Previous dose of PPSV23 vaccine received before age 65 Give: PCV13 at age 65 (or older), at least one year after the most recent PPSV23 dose. Give the final dose of PPSV23 6–12 months after PCV13, and at least five years after previous PPSV23 dose.

For more information, Children’s Hospital of Philadelphia (CHOP) has provided a great summary of the new recommendation.

2014-15 Influenza Vaccine Supply Update from the AAP

AAP staff has been gathering information to respond to your concerns about flu vaccine distribution and delivery. Here’s what you should know.

  • Several companies announced delays on original shipping projections
  • Offices have been receiving vaccine from September through the end of October
  • Shipments are late when compared to the last 2 years but more typical of previous years

We recognize the burden this places on your office, as you try to vaccinate all children in a timely manner. The information below will not speed the delivery of vaccine, but we do hope that it lessens some of your concerns. Click here to read more.

Are you maximizing your CPP rebate for the 2014-2015 rebate period?

As many of our members are aware, CPP provides a 2% rebate on Sanofi (mainline vaccines) and Merck (RotaTeq and Gardasil) products back to our member practices on an annual basis.  If a practice is maximizing their rebate, they can earn an average of about $1,000 per Pediatrician.  This CPP rebate is cash back to the practice.  Below are a few easy steps to make sure you are maximizing your practice’s rebate potential:

  • If you haven’t already, sign up for both the Sanofi Pasteur and Merck contracts.  Some practices don’t realize they are only signed up with one manufacturer and limit their opportunity to access more discounts and earn additional rebates.
  • Purchase your vaccines directly from Sanofi Pasteur and Merck.  If you purchase vaccines from a distributor (e.g. VaxServe), the manufacturers don’t know to link your practice to the CPP best discounts and your purchases will not count towards your CPP rebate.
  • If you have multiple practice sites, make sure all locations are signed up with both Sanofi Pasteur and Merck and that they are all purchasing directly through the manufactures.
  • Review your practice immunization rates.  If immunization rates are low for certain vaccines like Gardasil then you have an opportunity to provide important patient care and earn additional rebates on that vaccine.
  • Take advantage of CPP financial analysis tools to closely monitor your practice purchases and estimate your CPP rebate.  We can help make sure you’re not missing out on discounts and rebates.

If we can be of any assistance in maximizing your CPP rebates please don’t hesitate to contact us!

AAP NCE News: Invisible Threat Screening

Attendees at the AAP NCE in San Diego had the opportunity to view Invisible Threat, a documentary created by high school students in Carlsbad, CA that explores the science of disease and the risks facing a society that is under-vaccinated. The students did a tremendous job of analyzing the issues, presenting both scientific as well as anecdotal evidence and pulling it all together to stress the importance of vaccines to overall global health.  The video is now available for physicians to use in-office or for other educational purposes.  Simply go to the CHSTV Films website for more information.  Great job CHSTV Films!